<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873415</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-019</org_study_id>
    <nct_id>NCT03873415</nct_id>
  </id_info>
  <brief_title>Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males</brief_title>
  <official_title>Assessment of Regional Gastrointestinal Absorption of BMS-986165 Using Pharmacoscintigraphic Evaluation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986165 following Treatments A, B, C, and D</measure>
    <time_frame>Determined over 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986165 following Treatments A, B, C, and D</measure>
    <time_frame>Determined over 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986165 following Treatments A, B, C, and D</measure>
    <time_frame>Determined over 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986165 following Treatments A, B, C, and D</measure>
    <time_frame>Determined over 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent plasma elimination half-life (T-HALF) of BMS-986165 following Treatments A, B, C, and D</measure>
    <time_frame>Determined over 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs of body temperature</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AE)</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign of respiratory rate</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign of supine blood pressure</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage formulation and area of release varies between arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_label>Formulation C</arm_group_label>
    <arm_group_label>Formulation D</arm_group_label>
    <arm_group_label>Formulation E</arm_group_label>
    <arm_group_label>Formulation F</arm_group_label>
    <arm_group_label>Formulation G</arm_group_label>
    <arm_group_label>Formulation H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight â‰¥ 50 kg, at screening

          -  Estimated glomerular filtration rate (eGFR) &gt; 80 mL/min/1.732 calculated with the
             Chronic Kidney Disease Epidemiology Collaboration formula

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months of study drug administration) disease of the gut
             that, in the opinion of the Investigator or Medical Monitor, could impact upon the
             absorption of study drug

          -  Acute diarrhea, or constipation within 3 weeks prior to randomization

          -  Any major surgery within 4 weeks of randomization

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scintipharma</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

